Compare Eli Lilly And Co (LLY) vs Prospect Capital Corporation (PSEC) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

PSEC trades at $2.235, down 0.67% on the day, with a bearish technical signal and neutral oscillators. The stock shows a deeply discounted P/B ratio of 0.38 but alarming fundamentals, including a negative revenue of -$407M and a net income margin of -495.94% for 2025. Recent quarterly EPS has consistently beaten estimates, and the company maintains regular dividend payments. Analyst consensus is mixed, with 25% buy ratings but a majority hold recommendation.

The outlook for PSEC is highly speculative. The extreme discount to book value and high dividend yield present a potential value opportunity, but this is overshadowed by severe profitability issues and negative cash flow. Investment carries significant risk due to the company's inconsistent revenue history and bearish market sentiment, requiring careful consideration of the underlying asset quality.